Impact of CAR T-cell therapy in Earlier Lines of MM

Opinion
Video

A panel of experts examines the impact and potential of CAR T-cell therapy in earlier treatment lines for multiple myeloma, evaluating its efficacy, safety.

Video content above is prompted by the following:

  • Let’s talk about the use of CAR T-cell therapy in early R/R MM. Please share your thoughts on the following data:
  • CARTITUDE-4
  • KarMMa-3
  • How does the CAR T-cell fit into 2nd line treatment in your practice and in which patients do you use CAR T-cell in?
  • How does CAR T-cell therapy in the 2nd line affect your approach to front-line therapy for MM?
Recent Videos
A panel of 4 experts on multiple myeloma
A panel of 5 experts on multiple myeloma
A panel of 4 experts on multiple myeloma
A panel of 5 experts on multiple myeloma
Related Content
Community and academic oncologists discussed how effective communication between practices can enhance multiple myeloma outcomes.

Referrals From Community to Academia Enhances Multiple Myeloma Outcomes

Samer A. Al'Hadidi, MD;Frits van Rhee, MD, PhD;Appalanaidu Sasapu, MD
September 10th 2024
Article

Community and academic oncologists discussed how effective communication between practices can enhance multiple myeloma outcomes.

Registered nurses discuss research related to agents like ciltacabtagene autoleucel presented at the 2024 Oncology Nursing Society Congress.

Administering CAR T-Cell Therapy and Bispecific Agents in Nursing Practice

Ishmael Applewhite, BSN, RN-BC, OCN;Leslie Bennett, MSN, RN;Kathy Mooney, MSN, RN, ACNS-BC, BMTCN®, OCN®
May 6th 2024
Podcast

Registered nurses discuss research related to agents like ciltacabtagene autoleucel presented at the 2024 Oncology Nursing Society Congress.

Evaluating the Use of CAR T-Cell Therapy for Multiple Myeloma in Academic and Community Settings

Evaluating the Use of CAR T-Cell Therapy for Multiple Myeloma in Academic and Community Settings

ONCOLOGY Staff
August 27th 2024
Article

Strategies for treating patients with multiple myeloma who are eligible to receive CAR T-cell therapy in either community or academic practices were discussed in a recent Training Academy.

Experts discuss the current continuum of care for patients with EGFR exon 20 non–small cell lung cancer and findings from studies including the phase 2 CHRYSALIS trial.

Frontline Forum: Testing and Targeted Therapy in EGFR Exon20+ NSCLC

Alexander Spira, MD, PhD, FACP;Millie Das, MD;Joshua K. Sabari, MD;Misako Nagasaka, MD
September 4th 2023
Podcast

Experts discuss the current continuum of care for patients with EGFR exon 20 non–small cell lung cancer and findings from studies including the phase 2 CHRYSALIS trial.

Quadruplet Therapy May Be the New Frontline SOC in Multiple Myeloma

Quadruplet Therapy May Be the New Frontline SOC in Multiple Myeloma

ONCOLOGY Staff
August 23rd 2024
Article

Quadruplet therapy is making a run to be a potential standard of care in frontline multiple myeloma, according to a panel of experts.

The phase 1/2 LINKER-MM1 trial assessed linvoseltamab in relapsed/refractory multiple myeloma, of which the indication has been given a CRL by the FDA.

FDA Gives CRL to Linvoseltamab in Relapsed/Refractory Multiple Myeloma

Roman Fabbricatore;Ariana Pelosci
August 21st 2024
Article

The phase 1/2 LINKER-MM1 trial assessed linvoseltamab in relapsed/refractory multiple myeloma, of which the indication has been given a CRL by the FDA.